Background: The aim of this study was to develop a prediction model of progressive disease (PD) in breast cancer patients without measurable disease in first-line chemotherapy.
introduction Serum tumor markers have been widely used as tools for detecting specific cancers, measuring treatment response, and predicting prognosis. Cancer antigen 125 for ovarian epithelial cancer, prostate-specific antigen for prostate cancer, and alphafetoprotein or beta human chorionic gonadotropin for germ cell tumor are well-known markers [1] [2] [3] [4] .
Serum tumor markers for breast cancer have also been widely studied. The most well-known markers are carbohydrate antigen (CA) 15-3 and carcinoembryonic antigen (CEA) [5] . CA 15-3 alone, however, is not recommended as a marker for either diagnosis or detection of early recurrence of breast cancer according to the American Society of Clinical Oncology (ASCO) guidelines [6] . Because of insufficient data, the ASCO also does not recommend the use of CA 15-3 alone as a marker for monitoring response. It should be noted that the elevation of CA 15-3 between 4 and 6 weeks after initiation of a new therapy, i.e. spurious early rise (surge), indicates poor prognosis. The proportion of patients exhibiting a surge in CA 15-3 level after chemotherapy initiation was reported to be 4.8%, and patients with surge may respond more poorly to chemotherapy than those without surge [7] .
CEA is also not recommended as a marker for diagnosis or routine surveillance after primary therapy, and a surge in CEA level may also occur between 4 and 6 weeks after initiation of primary treatment. The ASCO does not recommend CEA measurement in patients with positive CA 15-3; thus, the CEA level provides only supplementary information. However, if sufficient data regarding other factors are available, rising CEA level can be a useful indicator of treatment failure in patients without measurable disease.
We herein documented the utility of CEA and CA 15-3 in predicting progressive disease (PD) in patients with breast cancer, especially in those without measurable disease. First, we developed an appropriate prediction model of PD using the CEA and CA 15-3 levels of patients with measurable disease who were enrolled in a phase III study conducted at our institution. We then validated the model in a clinical setting.
Finally, we applied it to patients without measurable disease. Our results could contribute to treatment monitoring and the decision-making process in patients without measurable disease.
patients and methods

patients used in model development
As a dataset for development of the prediction model, we used the CEA and CA 15-3 measurements of 97 patients who had enrolled in a multicenter phase III trial for first-line chemotherapy at the National Cancer Center Hospital between January 1999 and May 2003 [8] . Elevation of CEA and CA 15-3 levels at baseline was not required for eligibility. In this trial, the patients were randomized into three groups: those receiving six courses of AC therapy [doxorubicin (A), 40 mg/m 2 , day 1; cyclophosphamide (C) 500 mg/m 2 , day 1, once every 3 weeks (q3w)], those receiving six courses of docetaxel therapy (docetaxel, 60 mg/m 2 , q3w), and those receiving three courses of alternating AC therapy and docetaxel therapy. Trastuzumab combination therapy was not available for patients with metastatic or recurrent breast cancer during the enrollment period of this trial. The primary end point was the time to progression (TTP) of the firstline chemotherapy. TTP was defined as the time from the first day of chemotherapy until disease progression. Patients without disease progression were treated as censored observations at the last day of follow-up. We used the data from all patients enrolled in this trial from our institution. For the purpose of the present study, we retrieved the clinical records of 97 patients with measurable lesions whose response to chemotherapy had been prospectively assessed and whose CEA and CA 15-3 levels had been measured at intervals of up to 42 days in the phase III trial. After every two courses of chemotherapy, routine evaluations of the treatment responses of measurable lesions were carried out according to the World Health Organization criteria. All patients signed written informed consent forms that had been approved by the institutional review board for use in clinical trials and agreed to the review of their records and images for research purposes.
patients for external model verification
As an external validation dataset for verification of the prediction model, we used the data of 54 patients who met the following criteria: measurable disease according to RECIST version 1.0, treatment with first-line chemotherapy for metastatic breast cancer, and measurement of CEA and CA 15-3 levels at intervals of up to 42 days in a clinical setting at the National Cancer Center Hospital between January 2004 and January 2005. Elevation of CEA and CA 15-3 levels at baseline was not required for eligibility. These patients were selected from our database, and we conducted a review of their charts. All the patients had adequate bone marrow and organ function. The patients had been treated with AC therapy, docetaxel therapy, or weekly paclitaxel therapy (80 mg/m 2 ) consisting of three weekly cycles, followed by a week of rest. Trastuzumab combination therapy was also administered with the docetaxel or weekly paclitaxel therapy if the patient had a positive Human epidermal growth factor receptor 2 (HER2) status. The responses of all the patients to chemotherapy were evaluated according to the RECIST criteria, version 1.0 [9] . The treatment regimens were arbitrarily determined.
patients without measurable disease
As a dataset for testing the prediction model, we used the data of 63 patients meeting the following criteria: nonmeasurable disease according to RECIST version 1.0, treatment with first-line chemotherapy for metastatic breast cancer, and measurement of CEA and CA 15-3 levels at intervals of up to 42 days in a clinical setting at the National Cancer Center Hospital between January 1999 and December 2007. Elevation of CEA and CA 15-3 levels at baseline was not required for eligibility. These patients were selected from our database, and we conducted a review of their charts. Nonmeasurable lesions were defined according to the RECIST criteria, version 1.0. Lytic bone lesions or mixed lytic-blastic lesions with identifiable soft-tissue components that could be evaluated by cross-sectional imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) were considered to be nonmeasurable lesions. The treatment strategy for these patients was the same as that for the patients used for model verification.
serum tumor marker measurements
In all the patients in this study, complete blood cell count, blood chemistry, and serum tumor markers were measured using blood samples obtained within a week of chemotherapy initiation. Samples were obtained on day 1 of every course of chemotherapy administration to avoid cytolytic effects; the samples were immediately assayed in the laboratory of the National Cancer Center Hospital. The serum CEA and CA 15-3 values were measured using chemiluminescent enzyme immunoassays (sandwich principle) with commercially available kits: Lumipulse CEA-N and Lumipulse CA 15-3 (both kits, Fujirebio Diagnostics Inc., Tokyo, Japan). Quality control and calibration for all tumor marker measurements were strictly carried out using commercial reference control sera. The coefficients of intra-assay and interassay variation for all tumor markers were <10% [10] . The upper normal limits for CEA and CA 15-3 levels were 5 ng/ml and 25 U/ml, respectively.
development and verification of prediction model
To develop a prediction model, the documented response (PD or non-PD) and the two serum tumor marker levels in the development dataset were collected from the patients' medical charts as follows: baseline values, serum tumor marker values on day 1 of the second chemotherapy course, and serum tumor marker values on day 1 of the third chemotherapy course. The percent changes in the serum tumor marker values were expressed according to the following formulas: MARKER (I) = (marker value on day 1 of the second chemotherapy course 2 initial marker value)/initial marker value and MARKER (II) = (marker value on day 1 of the third chemotherapy course 2 marker value on day 1 of the second chemotherapy course)/marker value on day 1 of the second chemotherapy course.
Multivariate logistic regression models were used to derive the prediction model for PD. Several linear combinations of marker values included in the logistic model were selected from among CEA (I), CEA (II), CA 15-3 (I), CA 15-3 (II), and the levels of CEA and CA 15-3 at baseline. As a measure of accuracy, the area under the receiver operating characteristic curve (AUC) was used for each candidate prediction model and calculated by the bootstrap method as internal validation in order to reduce bias [11] . The bootstrap was replicated 300 times. The overall misclassification rate (OMR) of the model was also calculated. The best prediction model was determined by the maximum AUC. If several models with the same AUC were obtained, the more parsimonious model with lower OMR values was regarded as the better model. After development of the prediction model, the model was verified using the external validation dataset that comprised an independent consecutive series of 54 patients with metastatic or recurrent breast cancer who had received first-line chemotherapy in a clinical setting at the National Cancer Center Hospital between January 2004 and January 2005. The AUC, OMR, positive predictive value (PPV), and negative predictive value (NPV) for the external validation dataset were calculated to evaluate the performance of the prediction model. TTP was estimated using the Kaplan-Meier method and was statistically compared between the PD and non-PD groups as categorized by the developed prediction model using the log-rank test. Patients with no apparent disease progression were treated as censored observations at the last day of original article Annals of Oncology follow-up. A Cox regression analysis was used to estimate the hazard ratio (HR) and 95% confidence interval (CI).
prediction of PD in patients without measurable disease
We predicted PD in 63 patients without measurable disease using their CEA and CA 15-3 values. Using the developed prediction model, we categorized the 63 patients into PD and non-PD groups and compared the TTP between the two groups using the log-rank test and Cox regression analysis. Disease progression in patients without measurable disease was determined by treating physicians on the basis of physical signs, and patients with no apparent disease progression were treated as censored observations at the last day of follow-up. All statistical analyses were carried out using SAS version 9.1 (SAS Institute, Cary, NC).
results the best prediction model in the present study
The clinical characteristics of the patients in the development, verification, and application datasets are summarized in Table 1 .
Several candidate prediction models were evaluated on the basis of the AUC calculated by the bootstrap method. The five combinations of markers whose AUCs were high are given in Table 2 . As demonstrated in Table 2 , CEA (II) and evaluations of CEA and CA 15-3 levels at baseline contributed more to the prediction of PD than did the other variables. Interestingly, the elevation of CEA level at baseline did not independently reflect disease progression, with a calculated odds ratio of 0.897 (P = 0.915) and a negative estimated coefficient of 20.108. However, despite this, the inclusion of elevated CEA in the logistic model consistently improved AUC, and thus, we chose to include it in order to obtain the most accurate prediction model possible. The best prediction model, whose AUC was 0.731, defined the probability of PD as follows: probability of PD = e x /(1 + e x ), where e is the base of the natural logarithm. If the baseline CA 15-3 level was elevated, then x = (23.171 + 3.873 · CEA (II) + 2.543 · CA 15-3 (II) 2 0.108 · elevated CEA + 1.366 · elevated CA 15-3). The prediction rule was as follows: a calculated probability of PD ‡0.80 corresponded to a PD, while a calculated probability of response <0.80 corresponded to stable disease, partial response, or complete response. The OMR of the model using the development data was 0.093.
As an external validation, this model was verified using the external validation dataset, an independent consecutive series of 54 metastatic or recurrent breast cancer patients with measurable disease who were being treated in a clinical setting. These patients were categorized into two groups by the prediction model: a PD group comprising 6 patients and a non-PD group comprising 48 patients. The receiver operating characteristic curve is shown in Figure 1 , and its AUC, PPV, and NPV were 0.899, 0.958, and 0.67, respectively. Using the 0.80 cut-off threshold established in the data used for model development, the OMR for the validation data was 0.074. Thus, the prediction model accurately predicted the PD or non-PD of 90% of the clinical patients. Kaplan-Meier curves for TTP in the groups identified by the developed prediction model, shown in Figure 2A , and by the RECIST criteria, shown in Figure 2B , are very similar. According to Figure 2A , the difference in TTP between the two groups identified by the developed model was statistically significant (log-rank test, P < 0.001), and the HR for TTP in the non-PD group relative to the PD group was 0.104 (95% CI, 0.039-0.274).
Using the developed prediction model, we categorized the 63 patients used for application of the model into PD (10 patients) and non-PD (53 patients) groups. The Kaplan-Meier curves for TTP are shown in Figure 3 . According to Figure 3 , the difference in TTP between the two groups was statistically significant (log-rank test, P < 0.021), and HR for TTP in the non-PD group relative to the PD group was 0.1437 (95% CI, 0.212-0.901). The median survival times in the PD and non-PD groups were 2.52 months (95% CI, 2.00-8.46 months) and 7.84 months (95% CI, 7.08-9.64 months), respectively.
discussion
We developed and evaluated a prediction model for PD using serum measurements of CEA and CA 15-3 in breast cancer patients without measurable disease who underwent first-line chemotherapy. First, we developed the model from the data of a prospective study and then validated it in a clinical setting. Finally, we applied it to a set of breast cancer patients without measurable disease. The accuracy of the prediction model was tolerable in the sense that the TTP of both the validation set and the patients without measurable disease could be clearly separated and showed statistical significance. The calculated NPV of 0.67 was on the basis of a small sample size (NPV = 4/6), and we cannot definitively conclude that it is sufficiently high to be useful. Thus, careful attention should be paid to patients categorized as non-PD using the developed prediction model. However, considering its tolerable PPV, our model may be a valuable clue to physicians that recurrent or metastatic breast cancer disease may be progressive in patients without measurable disease who undergo chemotherapy. Both tumor markers are noninvasive, and when increasing between the second and third course of chemotherapy, serve as useful tools to help oncologists decide further continuation of the same chemotherapy regimen. According to RECIST version 1.1, lytic bone lesions or mixed lytic-blastic lesions with identifiable soft-tissue components that can be evaluated by cross-sectional imaging techniques such as CT or MRI are considered to be measurable lesions [12] . Bone scanning or other modalities for identifying bone metastasis can be used to confirm the diminishment of disease but not to evaluate treatment response. As indicated in RECIST version 1.1, lytic bone lesions meeting certain criteria can be measured, but our result is still useful for predicting PD in other patients without measurable disease.
Kim et al. reported that a CA 15-3 surge helps to predict poor response to chemotherapy. The surge is defined as a rise in the tumor marker level between 4 and 6 weeks after starting chemotherapy [7] . The model developed in this study used the increases in both CA 15-3 and CEA over the same time period; therefore, it may just reflect prognosis. However, when validating the model, we confirmed that the Kaplan-Meier curve of TTP in both the model and the RECIST had a very similar shape, which indicates that the model could possibly replace RECIST when evaluating PD, independent of the response to chemotherapy.
Tumor markers in other cancers, especially ovarian cancer, prostate cancer, and germ cell tumor, have been widely used [1] [2] [3] [4] . Rustin et al. presented results using MRC OV05/EORTC 55955 at the ASCO 2009 Annual Meeting. They concluded that there is no survival benefit from early treatment on the basis of a raised serum marker level alone and that, consequently, there is no value in the routine measurement of cancer antigen 125 in the follow-up of ovarian cancer patients. However, their study included patients who were in complete remission after firstline treatment; thus, cancer antigen 125 may be still useful for patients under treatment of the early prediction of PD. Furthermore, recognition of an increase in a tumor marker may signal the need to carry out earlier radiological tests that may result in withdrawal of ineffective chemotherapy, thus benefiting patients.
Although our data are valuable for patients without measurable lesions, the present study has some limitations. original article
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The data used here include patients who received skewed chemotherapy; therefore, the model developed needs to be validated in a prospective study. Furthermore, to determine the utility of the PD model, PD patients defined by our model and by RECIST should be randomized to receive one or the other of the two regimens or the continuation of the same regimen in order to measure survival.
In conclusion, our prediction model enables early prediction of a patient's probable response to therapy and could be used to identify patients who are likely to benefit from additional courses of chemotherapy. A prospective study including OMR, AUC, PPV, and NPV as evaluation criteria to confirm the utility of the model is warranted. 
